Multipoint Defocus Optics Technology Spectacle Lenses for Myopia Control in Children: A One-Year Interim Analysis of a Randomized Trial
In brief
New spectacle lenses were not inferior to established lenses for childhood myopia
In a one-year interim analysis of 194 children, multipoint-defocus lenses had similar average changes in nearsightedness to highly aspherical lenslet lenses: -0.74 versus -0.60 diopters. Eye growth was also not significantly different between groups. The findings support comparable results so far, but the ongoing trial's two-year analysis is still needed.
- Journal
- Translational vision science & technology (Q1)
- Published
- 5 October 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Yurui Zhang, Xiaotong Han, Ling Jin, Yi Ding, Decai Wang, Mingguang He, et al.
- PMID
- 42867309
- DOI
- 10.1167/tvst.15.10.14
Why clinicians should know about it
- Picked for Ophthalmology (top studies of the week, 18 October 2026): One‑year RCT interim analysis of myopia‑control lenses
Abstract
PURPOSE: To evaluate the one-year efficacy of novel partition multipoint defocus optics technology (PMDOT) lenses in slowing myopia progression, compared to lenses with highly aspherical lenslets (HAL). METHODS: This is a 1-year interim analysis of an ongoing 2-year, non-inferiority randomized controlled trial, in which 194 children ages 8 to 13 years with spherical equivalent refraction (SER) of -0.75 to -4.5 diopters (D) were randomized to either the PMDOT or HAL group. The primary outcome of the full trial was the mean between-group difference in SER change at 2 years, and the non-inferiority margin was -0.3 D. Secondary outcomes included changes in axial length (AL), choroidal thickness (ChT), and other biometric parameters, as well as best-corrected visual acuity (BCVA) at 2 years and subjective visual experience. Data from right eyes were used for the current analysis. RESULTS: The study included 102 children in the PMDOT group and 92 in the HAL group. After 1 year, the mean ± SD changes in SER and AL were not statistically significantly different between the two groups (PMDOT vs. HAL SER -0.74 ± 0.49 D vs. -0.60 ± 0.48 D, AL 0.26 ± 0.20 mm vs. 0.19 ± 0.19 mm) based on per-protocol (PP) analysis. The between-group difference in SER change at 12 months was -0.09 D (two-sided 97% confidence interval [CI], -0.26 to 0.09). Except for the change in anterior chamber depth in the PP analysis, no significant between-group differences were observed for any secondary outcomes. CONCLUSIONS: PMDOT lenses were not inferior to HAL lenses in controlling myopia progression. TRANSLATIONAL RELEVANCE: This trial demonstrated the clinical potential of PMDOT lenses for myopia control in schoolchildren.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.